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Abstract
Background: Hyperlipidemia secondary to protease inhibitors (PI) may abate by switching to anti-
HIV medications without lipid effects.
Method: An open-label, randomized pilot study compared changes in fasting lipids and HIV-1 RNA
in 104 HIV-infected adults with PI-associated hyperlipidemia (fasting serum total cholesterol >200
mg/dL) who were randomized either to a regimen in which their PI was replaced by abacavir 300
mg twice daily (n = 52) or a regimen in which their PI was continued (n = 52) for 28 weeks. All
patients had undetectable viral loads (HIV-1 RNA <50 copies/mL) at baseline and were naïve to
abacavir and non-nucleoside reverse transcriptase inhibitors.
Results: At baseline, the mean total cholesterol was 243 mg/dL, low density lipoprotein (LDL)-
cholesterol 149 mg/dL, high density lipoprotein (HDL)-cholesterol 41 mg/dL, and triglycerides 310
mg/dL. Mean CD4+ cell counts were 551 and 531 cells/mm3 in the abacavir-switch and PI-
continuation arms, respectively. At week 28, the abacavir-switch arm had significantly greater least
square mean reduction from baseline in total cholesterol (-42 vs -10 mg/dL, P < 0.001), LDL-
cholesterol (-14 vs +5 mg/dL, P = 0.016), and triglycerides (-134 vs -36 mg/dL, P = 0.019) than the
PI-continuation arm, with no differences in HDL-cholesterol (+0.2 vs +1.3 mg/dL, P = 0.583). A
higher proportion of patients in the abacavir-switch arm had decreases in protocol-defined total
cholesterol and triglyceride toxicity grades, whereas a smaller proportion had increases in these
toxicity grades. At week 28, an intent-to treat: missing = failure analysis showed that the abacavir-
switch and PI-continuation arms did not differ significantly with respect to proportion of patients
maintaining HIV-1 RNA <400 or <50 copies/mL or adjusted mean change from baseline in CD4+
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cell count. Two possible abacavir-related hypersensitivity reactions were reported. No significant
changes in glucose, insulin, insulin resistance, C-peptide, or waist-to-hip ratios were observed in
either treatment arm, nor were differences in these parameters noted between treatments.
Conclusion: In hyperlipidemic, antiretroviral-experienced patients with HIV-1 RNA levels <50
copies/mL and CD4+ cell counts >500 cells/mm3, substituting abacavir for hyperlipidemia-
associated PIs in combination antiretroviral regimens improves lipid profiles and maintains virologic
suppression over a 28-week period, and it simplifies treatment.
Background
Protease inhibitors (PIs) used as components of highly
active antiretroviral therapy (HAART) have been well doc-
umented to reduce both the morbidity and mortality asso-
ciated with HIV infection [1,2]. However, many PI-based
HAART regimens incur treatment-limiting side effects,
interactions with concomitant medications, high daily
pill burdens, and dietary and/or fluid requirements, mak-
ing adherence to treatment a challenge [3]. Even more
problematic from a long-term treatment perspective are
the metabolic adverse effects, such as hyperlipidemia,
insulin resistance, and lipodystrophy, which along with
HIV infection itself, may constitute major risk factors for
the development of coronary artery disease (CAD) [4].
The incidence of hyperlipidemia varies among PIs. The
Swiss HIV Cohort Study showed that over 470 days, HIV-
infected patients experienced a mean increase in total cho-
lesterol of 77 mg/dL with ritonavir (n = 46), 46 mg/dL
with nelfinavir (n = 21), 31 mg/dL with indinavir (n = 26),
and 4 mg/dL with non-PI-containing antiretroviral regi-
mens (n = 28) [5]. At the end of the study, total cholesterol
exceeded 240 mg/dL in 44% of the ritonavir group, 35%
of the indinavir group, 33% of the nelfinavir group, and
14% of the non-PI group. Other research has shown that
some of the more recently developed PIs, including
fosamprenavir and atazanavir, have a low likelihood of
causing significant lipid elevation or adversely affecting
the total cholesterol: high density lipoprotein (HDL) cho-
lesterol ratio [6-8]. Although HIV infection itself is associ-
ated with above-normal triglyceride levels due to disease-
related reduction in triglyceride clearance and increase in
de-novo hepatic lipogenesis [9], some PIs exacerbate this
lipid elevation by down-regulating low density lipopro-
tein (LDL)-receptor expression [10], interfering with the
proteasome-mediated degradation of activated nuclear
sterol regulatory element-binding protein-1 [11], and
reducing triglyceride clearance further [12].
Because PIs have been available for less than a decade, it
may be too early to confirm an association between PI
usage and a more rapid onset of CAD. Epidemiological
studies to date have reported varying findings regarding a
PI-CAD link [13-15]. Until questions about such a possi-
ble link are resolved, it appears prudent to treat HIV-
infected patients who have CAD risk factors with combi-
nations of antiretroviral agents that produce maximal
virologic suppression with the fewest lipid-elevating
effects and metabolic adverse events.
Unlike most PIs, the nucleoside reverse transcriptase
inhibitor (NRTI) abacavir is administered as just one tab-
let twice daily with no requirements regarding extra
hydration or dosing with or without meals [16]. Abacavir
is unlikely to be involved in drug interactions because it
does not affect CYP3A4 drug metabolism, its use does not
affect lipids or metabolic parameters, and it does not
cause lipodystrophy [16]. These features of abacavir have
prompted its use in substituting for components of
HAART regimens in order to simplify treatment and to
obviate the risk of drug interactions, fat maldistribution,
and metabolic complications [17]. HAART regimens con-
taining abacavir have been shown in direct comparative
trials in HIV-infected patients with a baseline viral load
<100,000 copies/mL to be as effective as nelfinavir-and
indinavir-containing HAART in suppressing viral load and
increasing CD4+ cell counts without inducing hyperlipi-
demia, insulin resistance, or central adiposity [18-21]. In
patients with a baseline viral load ≥ 100,000 copies/mL,
abacavir in combination with lamivudine and zidovudine
has been shown to suppress viral load and increase CD4+
cell counts as well as nelfinavir-containing HAART [20],
and was as effective as indinavir-containing HAART in one
trial [18] but not in another [21]. In view of these find-
ings, we conducted a 28-week, open-label pilot study
(ESS40003) to compare the changes in PI-associated
hyperlipidemia (fasting serum total cholesterol >200 mg/
dL) in treatment-experienced HIV-infected patients with
HIV-1 RNA <50 copies/mL who either substituted
abacavir for the PI component in their regimen or contin-
ued the same PI-containing regimen.
Methods
Patient selection
Male and non-pregnant, non-lactating female outpatients
were eligible for study enrollment if they were at least 18
years of age; had HIV-1 infection (documented by HIV-1
antibody enzyme-linked immunosorbent assay and con-
firmed by Western blot test of HIV-1 antibody, or positive
HIV-1 blood culture, positive HIV serum antigen, orBMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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plasma viremia); had fasting serum total cholesterol >200
mg/dL; were stabilized on a well-tolerated PI-containing
antiretroviral regimen for >3 months (either 2 NRTIs + 1
PI, or 2 NRTIs + 2 PIs if one PI was ritonavir); were naïve
to abacavir and all non-nucleoside reverse transcriptase
inhibitors (NNRTIs); and if their two most recently
reported consecutive plasma HIV-1 RNA values were <400
copies/mL prior to screening and HIV-1 RNA was <50
copies/mL at screening. CD4+ cell counts could be of any
magnitude. Patients were also eligible if their HAART reg-
imen had changed due to intolerance (one drug substitu-
tion, such as a PI for another PI and/or an NRTI for
another NRTI) >12 weeks prior to study start; or if their
initial HAART regimen consisted of 2 NRTIs followed
within 1 year by the addition of a PI. Patients were
excluded from the study if they had genetically-related
lipid disorders (familial lipoprotein lipase deficiency,
apoprotein CII deficiency, type 3 hyperlipoproteinemia,
hypercholesterolemia, hypertriglyceridemia, or combined
hyperlipidemia); took a hypolipidemic or antidiabetic
drug within 30 days of screening; had an AIDS-defining
opportunistic infection or disease within 30 days of study
entry; had a history of angina, anginal symptoms, and/or
myocardial infarction; were substance abusers; or had a
malabsorption syndrome that could interfere with
absorption of the study medications. Patients provided
written informed consent to participate in the study.
Study design and treatment
This Phase IV, parallel group, active control, randomized,
open-label, multicenter trial was conducted between
November 1999 and November 2001 at 44 outpatient
sites in the United States. An Institutional Review Board
approved the study protocol at each site. To determine
study eligibility, study candidates underwent a medical
history, physical examination, CDC classification, clinical
chemistry, hematology, and β-human chorionic gonado-
tropin test (women of childbearing age only) at the
screening visit within 14 days pre-study. Patients meeting
entry criteria at screening were randomized to either con-
tinued therapy with their current PI-containing antiretro-
viral regimen or to the same regimen with abacavir (300
mg twice daily) substituted for the PI(s). Abacavir was
supplied as 300-mg tablets of Ziagen® (GlaxoSmithKline,
Research Triangle Park, North Carolina). In the abacavir-
switch arm, patients received both abacavir and the hyper-
lipidemia-associated PI with their usual two-NRTI back-
ground combination for the first 4 weeks, after which the
PI component of the regimen was discontinued. Co-
administration of abacavir and the PI was done during the
first 4 weeks to make sure that there was virologic cover-
age in case a patient developed a suspected abacavir-
related hypersensitivity reaction, which would have neces-
sitated stopping abacavir. Blood was sampled for lipid,
viral load, and laboratory value measurements from
fasted patients at baseline, and at weeks 4, 8, 12, 20, and
28. Patients who experienced HIV-1 RNA breakthrough
(defined as HIV-1 RNA values between 50 and 1000 cop-
ies/mL by Roche Amplicor Ultrasensitive Assay) during
the study period could receive intensification with efa-
virenz 600 mg once daily.
Assessment of lipids
A complete fasting lipid panel was obtained from blood
samples at baseline and at weeks 4, 8, 12, 20, and 28 to
allow measurement of the primary study endpoint
(change from baseline in fasting serum total cholesterol)
and secondary study endpoints (change from baseline in
LDL-cholesterol, very low density lipoprotein (VLDL)-
cholesterol, high density lipoprotein (HDL)-cholesterol,
and triglycerides). Apolipoproteins B and E, free fatty
acids, and LDL subfractions were measured at baseline
and week 28. Direct LDL-cholesterol was measured in all
patients at baseline, week 4, and week 28, as well as any
treatment visit at which time a fasting triglyceride >400
mg/dL was observed.
Fasting serum total cholesterol and triglyceride levels were
measured enzymatically by using cholesterol/HP reagent
(Roche Diagnostics, Indianapolis, Indiana) and triglycer-
ide reagent (GPO-Trender) (Roche Diagnostics, Ibid).
HDL-cholesterol was measured enzymatically in the
supernatant formed following centrifugation of serum
mixed with a polyanion dextran sulfate/divalent magne-
sium solution (Roche Diagnostics, Ibid). LDL- and VLDL-
cholesterol were estimated by the Friedewald equation
[22]. Direct LDL-cholesterol was measured by a nonionic
detergent method using alpha-cyclodextrin/4-aminoanti-
pyrin (Roche Diagnostics, Ibid.). Apolipoprotein B was
measured using the apolipoprotein B antigen-antibody
reaction method employing the Beckman IMMAGE
Immunochemistry System (Beckman Instrument, Brea,
California), and apolipoprotein E by a phosphate buffer/
anti-human apolipoprotein E method employing a Wako
Apolipoprotein Calibrator (WAKO Chemicals, Rich-
mond, Virginia). LDL subfractions were measured by elec-
trophoresis (Pacific Biometrics, Seattle, Washington) [23],
and non-esterified free fatty acids were measured by the
WAKO enzymatic colorimetic method (WAKO Chemi-
cals, Ibid.).
Four protocol-defined toxicity grades for hyperlipidemia
were assigned during the study for serum cholesterol
(Grade 1 for values >1–1.3 times the upper limit of nor-
mal [ULN], Grade 2 for >1.3–1.6 times the ULN, Grade 3
for >1.6–2 times the ULN; and Grade 4 for >2 times the
ULN) and serum triglycerides (Grade 1 for ULN-399 mg/
dL, Grade 2 for 400–750 mg/dL, Grade 3 for 751–1200
mg/dL, and Grade 4 for >1200 mg/dL).BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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Efficacy assessment
Changes in HIV-1 RNA levels and CD4+ cell counts were
secondary endpoints in this study. Plasma HIV-1 RNA lev-
els were measured in blood samples at screening and at all
study visits using both the Roche AMPLICOR PCR Stand-
ard 1.0 assay (lower limit of quantitation [LLOQ] 400
copies/mL) and the Roche PCR assay Amplicor HIV-1
MONITOR UltraSensitive Version 1.0 (LLOQ 50 copies/
mL) (both assays from Roche Diagnostics, Branchburg,
New Jersey). Virologic failure was defined as HIV-1 RNA
>1000 copies/mL on two occasions at least 1 week apart.
CD4+ cell counts were determined by flow cytometry at
baseline, and at weeks 4, 12, 20, and 28.
Safety assessment
Frequency and severity of all clinical and laboratory
adverse experiences were assessed at each visit. A cardio-
vascular disease risk factor assessment was conducted at
baseline only. Body mass index (BMI) and waist-to-hip
ratio (WHR) were measured at baseline and at weeks 4, 8,
12, 20 and 28. Three types of waist measurements were
conducted: mid, minimal, and umbilicus. Insulin resist-
ance measures (C-peptide and fasting insulin to glucose
ratio) were assessed at baseline and at weeks 4, 8, 12, 20,
and 28. Leptin and lactate were measured at baseline and
week 28.
Diagnosis of possible abacavir-related hypersensitivity
reaction was to be considered if the following multi-organ
signs and symptoms appeared in a patient following initi-
ation of abacavir: fever, rash, gastrointestinal symptoms
(nausea, vomiting, diarrhea, or abdominal pain), leth-
argy, or malaise with or without concomitant respiratory
symptoms (dyspnea, sore throat, cough), musculoskeletal
symptoms (myalgia, myolysis, arthralgia), headache, par-
esthesia, and edema. No rechallenge of abacavir was per-
mitted in patients developing this syndrome. The
definition and usual clinical presentation of abacavir-
related hypersensitivity has been defined previously
[24,25].
Adherence and health outcomes assessments
Adherence was assessed by the Patient Medication Adher-
ence Questionnaire-7 (PMAQ-7) [26]. The PMAQ-7 is a
self-reported measure of adherence that patients com-
pleted at baseline and at weeks 4, 8, 12, 20, and 28 (or
upon permanent discontinuation due to virologic failure
or toxicity). In the PMAQ-7, patients were asked to indi-
cate the number of doses of each medication they took
during each of the previous 7 days. An overall regimen
adherence rate was calculated at each week as the propor-
tion of doses actually taken relative to the number of
doses prescribed summed across each medication within
the regimen. The PMAQ-7 also measured barriers and
motivators to adherence.
Health-related quality of life (QOL) was evaluated using
the Medical Outcomes Study 36-item Short Form Health
Survey (SF-36) [27], which patients completed at baseline
and at study weeks 12 and 28. Healthcare resource utiliza-
tion (total health care visits, emergency room visits, inten-
sive care hospitalizations [nights], general ward
hospitalizations [nights], outpatient clinic visits, home
care visits, and long-term care visits [nights]) was assessed
at weeks 4, 8, 12, 20 and 28.
Statistical analysis
A sample size of 80 patients per treatment arm was
deemed necessary for 80% power to detect a difference of
20 mg/dL in fasting total cholesterol between groups
using a two-group t-test with a two-sided significance level
of 0.05, assuming a dropout rate of 20%. This sample size
calculation is based on data from NZTA4002, in which
the standard deviation of total cholesterol in the nelfina-
vir/zidovudine/lamivudine group at baseline was 39.5
mg/dL.
The primary efficacy population was the intent-to-treat
(ITT) population, which consisted of all patients who
were randomized into the study. The safety population
consisted of all randomized patients who received at least
one dose of study drug. Analysis of covariance (ANCOVA)
was used to compare the least squares means (LSM) of the
two treatment groups. The LSM represented the mean
value adjusted for the average value of the covariate from
both treatment groups. LSMs of change from baseline in
serum lipids (total, LDL, VLDL, and HDL-cholesterol, LDL
subfractions, triglycerides, free fatty acids), apolipopro-
tein B, apolipoprotein E, leptin, C-peptide, glucose, insu-
lin, and lactate were reported. The ANCOVA model
included terms for treatment group, baseline value of the
variable of interest, PI strata and gender.
Two types of analyses were performed with HIV-1 RNA
data: the ITT: observed analysis and the ITT missing equals
failure analysis (ITT: M = F). In the ITT: observed analysis,
only available assessments were used (no imputation for
missing values), regardless of whether the patient was still
receiving their original therapy. In the ITT: M = F analysis,
all missing values were considered as failure. Proportions
of patients with HIV-1 RNA <400 copies/mL and <50 cop-
ies/mL were compared between treatment groups with a
95% confidence interval (CI) on the difference between
proportions.
Differences in domain scores to the SF-36 and the PMAQ-
7 were compared using the Wilcoxon rank sum test. Dif-
ferences between treatment arms in the incidence of treat-
ment-related adverse events by body system were
evaluated by Fisher's Exact test. A P value of 0.05 was con-
sidered statistically significant.BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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Results
Patient characteristics and disposition
Of 104 patients enrolled in the study, 52 were rand-
omized to the abacavir-switch arm and 52 to the PI-con-
tinuation arm (Figure 1). Most of the patients were males
(89%), and the median age was 42 years (Table 1). The
study population was ethnically diverse; approximately
one-half were Caucasian, one-quarter African American,
and one-quarter Hispanic. Mean CD4+ cell counts were
551 and 531 cells/mm3 in the abacavir-switch and PI-con-
tinuation arms, respectively. About two-thirds of the
patients were HIV Category A. The abacavir-switch and PI-
continuation arms were well matched with respect to
mean baseline HIV-1 RNA levels (1.727 vs 1.699 log10
copies/mL, P = 0.062), total cholesterol (244 vs 241 mg/
dL), LDL-cholesterol (149 vs 149 mg/dL), VLDL-choles-
terol (68 vs 56 mg/dL), HDL-cholesterol (39 vs 42 mg/
dL), triglycerides (340 vs 280 mg/dL), CAD risk factors
(Table 1), and specific PI used immediately pre-study
(>80% receiving either nelfinavir or indinavir). There
were no significant differences between treatment arms
with respect to baseline BMI, waist-to-hip ratios or insulin
resistance. During treatment, the background NRTIs used
in the abacavir-switch and PI-continuation arms were
similar and included most commonly the lamivudine 150
mg/zidovudine 300 mg combination tablet (Combivir®
[GlaxoSmithKline, Ibid.], 52% vs 47%), stavudine (36%
vs 42%), lamivudine (32% vs 40%), and zidovudine (6%
vs 2%).
A similar number of patients withdrew prematurely from
the study for the reasons delineated in Table 1. Compara-
tively more patients withdrew due to adverse events in the
abacavir-switch arm (7/52 vs 1/52) and due to consent
withdrawn in the PI-continuation arm (0 vs 9/52 [all
withdrawals occurred after the patients learned they were
not receiving abacavir]). The difference between the two
treatment arms regarding number of premature withdraw-
als due to the sum of adverse events plus virologic failure
was not statistically significant (P = 0.144). No patient
required efavirenz intensification of their treatment
regimen.
Changes in lipids
In the ITT analysis, the abacavir-switch arm experienced
greater reductions in total cholesterol (Figure 2) and LDL-
cholesterol (Figure 3) than the PI-continuation arm over
the entire study period, with differences between treat-
ment arms being statistically significant from week 8
onward. At week 28, patients in the abacavir-switch arm
had a significantly greater LSM decrease from baseline in
total cholesterol (-42 vs -10 mg/dL; P <0.001), LDL-cho-
lesterol (-14 vs +5 mg/dL; P = 0.016), LDL direct-choles-
terol (-15 vs +1 mg/dL; P = 0.028), VLDL-cholesterol (-27
vs -7 mg/dL; P = 0.019), triglycerides (-134 vs -36 mg/dL;
P  = 0.019), apolipoprotein B (-23 vs -11 mg/dL; P  =
0.031), and apolipoprotein E (-2 vs -1 mg/dL; P = 0.021)
versus the PI-continuation arm. Over the study period, no
significant differences were observed between the
abacavir-switch or PI-continuation arms with respect to
LDL subfractions (particle size A and major class) or HDL-
cholesterol (LSM change from baseline at week 28, +0.2 vs
+1.3 mg/dL, P = 0.583; LSM at week 28, 40 vs 41 mg/dL).
The abacavir-switch arm showed a trend for greater LSM
reduction from baseline in free fatty acids (-0.3 vs -0.2
mEq/L; P = 0.052).
The LSM value for total cholesterol was below the
National Cholesterol Education Program Adult Treatment
Panel III (NCEP ATP III) goal value (<200 mg/dL) in the
abacavir-switch arm (198 mg/dL); however, it remained
above this value in the PI-continuation arm (230 mg/dL).
The LSM LDL-cholesterol level at week 28 was 133 mg/dL
in the abacavir-switch arm and 153 mg/dL in the PI-con-
tinuation arm (P = 0.016). A higher proportion of patients
in the abacavir-switch arm had shifts to lower toxicity
grades as compared to the PI-continuation arm, whereas a
lower proportion in the abacavir-switch arm had shifts
from baseline in cholesterol to more severe toxicity grades
(Figure 4)
Profile of patient enrollment and discontinuations through 28  weeks of treatment Figure 1
Profile of patient enrollment and discontinuations through 28 
weeks of treatment.
76 Patients failed screening 
because they did not meet 
inclusion criteria or were 
disqualified because they 
met exclusion criteria
52 Patients assigned to
PI-continuation regimen 
52 Patients assigned to 
abacavir-switch regimen 
104 Patients randomized
11  Discontinued study
  1  Adverse events 
  1  Lost to follow-up 
  9  Consent withdrawn 
  0  Virological failure 
  0  Other reasons 
  0  Death 
14  Discontinued study
  7  Adverse events 
  1  Lost to follow-up 
  0  Consent withdrawn 
  3  Virological failure 
  3  Other reasons 
  0  Death 
38 Completed 28-week 
randomized treatment
41 Completed 28-week 
randomized treatment
180 Patients screened BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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Table 1: Characteristics and disposition of the study patients (intent-to-treat population)
Characteristic Abacavir-switch arm 
(N = 52)
PI-continuation arm 
(N = 52)
Total study population 
(N = 104)
Age, y
Median (range) 43 (23–64) 42 (25–62) 42 (23–64)
Sex, No. (%)
Male 46 (88) 47 (90) 93 (89)
Female 6 (12) 5 (10) 11 (11)
Race, No. (%)
Caucasian 26 (50) 28 (54) 54 (52)
African American 16 (31) 11 (21) 27 (26)
Hispanic 10 (19) 13 (25) 23 (22)
Mean HIV-1 RNA, log10 copies/mL (SD) 1.73 (0.16) 1.69 (0.04) 1.71 (0.06)
Mean CD4+ cell count, cells/mm3 (SD) 551 (226) 531 (233) 541 (229)
Mean weight, kg (SD) 79.3 (16.8) 80.4 (16.6) 79.8 (16.7)
Mean BMI, kg/cm2 (SD) 25.9 (4.5) 26.4 (4.9) 26.1 (4.7)
Mean waist-to-hip ratio 0.94 (0.06) 0.93 (0.07) 0.94 (0.06)
CDC Class, n (%)
Category A 33 (63) 34 (65) 67 (64)
Category B 10 (19) 11 (21) 21 (20)
Category C 9 (17) 7 (13) 16 (15)
Mean (SD) total cholesterol, mg/dL 244 (45) 241 (44)
Mean (SD) LDL cholesterol, mg/dL 149 (34) 149 (30)
Mean (SD) HDL cholesterol, mg/dL 39 (15) 42 (14)
Mean (SD) triglycerides, mg/dL 340 (213) 280 (282)
Coronary artery disease risk factors, n (%)* 34 (65) 26 (50) 60 (58)
Age 18 (35) 12 (23) 30 (29)
Family history 4 (8) 4 (8) 8 (8)
Cigarette smoking 19 (37) 13 (25) 32 (31)
Hypertension 5 (10) 8 (15) 13 (13)
Low HDL 10 (19) 4 (8) 14 (13)
Diabetes mellitus 3 (6) 0 3 (3)
Antiretroviral medications taken prior to screening, n (%)
Any 28 (56) 20 (44) 48 (46)
NRTIs
Zidovudine 16 (32) 9 (20) 25 (24)
Lamivudine 12 (24) 8 (18) 20 (19)
Stavudine 5 (10) 2 (4) 7 (7)
Didanosine 7 (14) 0 7 (7)
Zalcitabine 3 (6) 0 3 (3)
NNRTIs
Efavirenz 1 (2) 0
PIs
Indinavir 11 (22) 8 (18) 19 (18)
Nelfinavir 4 (8) 2 (4) 6 (6)
Ritonavir 2 (4) 1 (2) 3 (3)
Saquinavir 2 (4) 0 2 (2)
PI used at screening
Nelfinavir 22 (42) 21 (40) 43 (41)
Indinavir 21 (40) 22 (42) 43 (41)
Saquinavir SGC 6 (12) 6 (12) 12 (12)
Amprenavir 2 (4) 2 (4) 4 (4)BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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Ritonavir 1 (2) 1 (2) 2 (2)
Premature withdrawal from study, n (%) 14 (27) 11 (21) 25 (24)
Adverse event 7 (13) 1 (2) 8 (8)
Consent withdrawn 0 9 (17) 9 (9)
Lost to follow-up 1 (2) 1 (2) 2 (2)
Protocol violation 2 (4) 0 2 (2)
Protocol-defined virologic failure 3 (6) 0 3 (3)
Other 1 (2) 0 1 (1)
*Cumulative coronary artery disease risk factors in the abacavir-switch arm: 0 factors = 18; 1 factor = 16; 2 factors = 12; 3 factors = 5; 4 factors = 
1. Cumulative coronary artery risk factors in the PI-continuation arm: 0 factors = 26; 1 factor = 12; 2 factors = 13; and 3 factors = 1.
Abbreviations: AIDS = acquired immune deficiency syndrome; ART = antiretroviral therapy; CDC = Centers for Disease Control; HDL = high 
density lipoprotein; HIV-1 = human immunodeficiency virus type 1; LDL = low density lipoprotein; LSM = least squares mean; SD = standard 
deviation; SGC = soft gel capsule.
Least squares mean change from baseline in fasting serum total cholesterol Figure 2
Least squares mean change from baseline in fasting serum total cholesterol.
Table 1: Characteristics and disposition of the study patients (intent-to-treat population) (Continued)
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Changes in serum triglycerides in the two treatment
groups paralleled the changes in total cholesterol. At week
28, the LSM reduction in triglycerides was significantly
greater in the abacavir-switch arm than the PI-continua-
tion arm (-134 vs -36 mg/dL, P = 0.019) (Figure 5). A
higher proportion of patients in the abacavir-switch arm
had decreases in the triglyceride toxicity grade as com-
pared to the PI-continuation arm, whereas a lower pro-
portion in the abacavir-switch arm had increases in
triglyceride toxicity grade (Figure 6).
Efficacy
In the ITT: M = F analysis, no differences were observed
between the abacavir-switch and PI-continuation treat-
ment arms at any time during the study regarding propor-
tions of patients achieving undetectable HIV-1 RNA. At
week 28, HIV-1 RNA was <400 copies/mL in 69% [36/52]
and 77% [40/52] of patients in the abacavir-switch and
PI-continuation arms, respectively (P = 0.508; 95% CI [-
0.25, 0.09]), and <50 copies/mL in 62% [32/52] and 75%
[39/52] of patients in these respective groups (P = 0.206;
95% CI [-0.31, 0.04]).
The ITT: observed analysis showed that HIV-1 RNA
remained <400 copies/mL in ≥ 90% of patients over the
entire study duration. At week 28, the proportion of
patients with HIV-1 RNA <400 copies/ml was 90% [36/
40] and 100% [40/40] in the abacavir-switch and PI-con-
tinuation arms, respectively(P = 0.116; 95% CI [-0.19, -
0.11]) (Table 2). A significantly higher proportion of
patients in the PI-continuation arm achieved HIV-1 RNA
Least squares mean change from baseline in fasting serum LDL-cholesterol Figure 3
Least squares mean change from baseline in fasting serum LDL-cholesterol.
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levels <50 copies/ml at week 28 (98% [39/40] vs. 80%
[32/40]; P = 0.029; 95% CI [-0.31, -0.04]).
No differences were observed regarding time to virologic
breakthrough (P  = 0.961). Three patients (6%) in the
abacavir-switch arm were protocol-defined virologic fail-
ures. However, one of these patients remained on a 2-
NRTI/abacavir regimen after withdrawing from the study
and his viral load declined. The second of these patients
was noncompliant and discontinued his antiretroviral
treatment prior to the confirmation blood draw for viro-
logic failure. The third virologic failure in the abacavir-
switch arm had a history of prior dual nucleoside therapy
for >1 year.
At baseline, the mean CD4+ cell counts were 551 and 531
cells/mm3  in the abacavir-switch and PI-continuation
arms, respectively. Changes in CD4+ counts over the
study period were similar. At week 28, the LSM CD4+ cell
counts were 514 and 526 cells/mm3, respectively, with the
LSM difference from baseline being -13 and -1 cells/mm3,
respectively (P = 0.597).
Adherence and health outcomes assessments
PMAQ-7 results showed no apparent differences between
the abacavir-switch and PI-continuation arms in overall
adherence at week 28 (90% vs 94%) or in the Social Sup-
port, Adaptability, Knowledge and Attitudes, and Memory
and Recall domains. However, the abacavir-switch arm
had significantly higher scores in the Scheduling and Tim-
ing domain for all study visits (P ≤ 0.027 at each week)
and in the Physical Effects domain for all visits (P < 0.05)
except those at weeks 4 and 28. In answer to the PMAQ-7
questions "it is easy for me to take my medicines at the
time I am supposed to" and "my medicines are
convenient to take", more patients in the abacavir-switch
arm answered "definitely true" at week 28 (51% vs 35%
and 63% vs 29%, respectively). In the SF-36, the week 28
QOL scores did not differ between treatment arms for
most domains, except Vitality (in favor of the PI-continu-
Changes in cholesterol toxicity grade Figure 4
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ation arm; P = 0.042) and Health (in favor of the abacavir-
switch arm; P = 0.013). There were no differences between
treatment arms with respect to any health care utilization
parameter.
Safety
Substitution of PIs with abacavir in HAART regimens was
generally well tolerated. No significant differences
between treatment arms were observed for cardiovascular,
endocrine/metabolic, hepatobiliary tract/pancreatic
events, lower respiratory events, musculoskeletal, neurol-
ogy, psychiatric, or skin adverse events, although more
gastrointestinal (P = 0.002) and non-site specific adverse
events (P = 0.003) were observed in the abacavir-switch
arm. Treatment-related adverse events reported by >5% of
patients in the abacavir-switch arm included nausea (12/
50 [14%]), fatigue (6/50 [12%]), diarrhea (4/50 [8%]),
and depressive disorders (3/50 [6%]). Two patients (4%)
in the abacavir-switch arm experienced possible abacavir-
related hypersensitivity reactions. Adverse events leading
to treatment withdrawal in 7 patients in the abacavir-
switch arm included possible abacavir-related hypersensi-
tivity reaction (2), mild nausea (2), mild shortness of
breath/tachycardia (1), mild disorientation (1), and com-
bination of mild diarrhea, facial edema/numbness and
malaise (1). Hyperlipidemia led to treatment withdrawal
in 1 patient in the PI-continuation arm. No differences
between the two treatments were observed in body
weight, waist-to-hip ratio, BMI, lactate, leptin, glucose,
insulin, or C-peptide.
Least squares mean change from baseline in fasting serum triglycerides Figure 5
Least squares mean change from baseline in fasting serum triglycerides.
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Discussion
The results of this study indicate that in hyperlipidemic,
virologically suppressed, immunocompetent antiretrovi-
ral-experienced patients (HIV-1 RNA <50 copies/mL,
CD4+ counts >500 cells/mm3), substituting abacavir for
hyperlipidemia-associated PIs in HAART regimens
improves lipid profiles and maintains virologic suppres-
sion over a 28-week period. The lipid findings are
consistent with those of other studies in which abacavir
was substituted for PIs in HAART regimens [28-33]. How-
ever, unlike the other studies, ESS40003 evaluated a
population consisting entirely of patients who were
hyperlipidemic at baseline. Also, unlike two previous
studies that reported lipid changes following abacavir
substitution [29,30], ESS40003 measured fasting  lipids
rather than lipids in a non-fasted state (which may con-
found results). Thus, true differences between abacavir
and PI-containing regimens could be determined, and
lipid criteria established by the NCEP ATP III could be
applied [34]. In addition to monitoring changes in choles-
terol and triglycerides, ESS40003 measured changes in
other laboratory values known to contribute to atherogen-
esis (apolipoproteins B and E, LDL subfractions, and indi-
cators of changes in lipid processing [leptin and free fatty
acids]) to gain a better understanding of the extent of the
improvement in lipid profile following the switch to
abacavir. Substitution of hyperlipidemia-associated PIs
with abacavir was expected to improve lipid profiles
Changes in triglycerides toxicity grade Figure 6
Changes in triglycerides toxicity grade.
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because results of direct comparisons of abacavir/NRTI
regimens with PI/NRTI regimens (same NRTIs adminis-
tered) in antiretroviral-naïve patients have shown no sig-
nificant effects on lipids with abacavir/NRTI-containing
regimens [18-20].
Cross-trial comparisons with other abacavir-switch stud-
ies regarding lipid changes are limited by differences
between studies in prevalence and severity of
hyperlipidemia prior to the switch, specific PIs
administered, pre-existing CAD risk factors of the particu-
lar patients enrolled, and stipulated dietary and exercise
restrictions. Nevertheless, some generalizations can be
made between the lipid changes noted in ESS40003 and
those reported in other abacavir-switch studies [28-33].
First, as in these other studies, decreases in total choles-
terol, LDL-cholesterol, and triglycerides occurred rapidly
following the switch to abacavir, with statistically signifi-
cant differences noted between treatment arms within 4
weeks. Second, as would be expected, the magnitude of
the reduction in total- and LDL-cholesterol and triglycer-
ides at week 28 in our study was markedly greater than
that reported in studies that included normolipidemic as
well as hyperlipidemic patients. Third, as in the other
studies, switching from a PI to abacavir had no significant
effect on HDL-cholesterol.
The small reduction in lipids observed in the PI-continu-
ation arm may have occurred because patients were aware
that their lipids were being monitored, and therefore may
have exerted more self-control than usual regarding their
dietary fat intake and frequency of smoking, or may have
exercised more (not monitored in this study). A similar
phenomenon was observed over 48 weeks in another PI-
to-abacavir switch study, CNA30017 [29]. As no change in
body weight, BMI, or waist-to-hip ratio was observed in
our study in either group, anthropomorphic parameters
were unlikely to have accounted for the decreases in lipids
observed during this study. The 28-week duration of this
study may have been too short to see significant changes
in BMI or waist-to-hip ratios. However, in the Swiss HIV
Cohort Study, substitution of abacavir for a PI was not
associated with a change in waist-to-hip ratios even after
48 weeks post-switch [30].
Maintenance of virologic suppression and increases in
CD4+ cell count over the 24-week period following the
switch to abacavir were expected in view of the lack of
change in these surrogate markers previously observed in
abacavir-switch studies conducted over 48 weeks to 1 year
[27,29].
The abacavir-containing regimen was generally well-toler-
ated, and the type and incidence of adverse events (nota-
bly fatigue and nausea) and rare occurrence of suspected
abacavir-related hypersensitivity reactions were consistent
with what has been reported in other clinical trials [16].
New adverse events in the PI-continuation arm were not
expected as patients had been stabilized on this treatment
for >3 months. This fact may have accounted for the com-
paratively lower incidence of GI adverse events in the PI-
continuation arm than in the abacavir-switch arm, a find-
ing that has not been observed in direct comparisons of
abacavir with PIs (indinavir or nelfinavir) administered
with the same background antiretroviral drugs [18,19,21].
Table 2: Proportion of patients with HIV-1 RNA <400 copies/mL and <50 copies/mL
Week HIV-1 RNA <400 copies/mL, n/N (%) HIV-1 RNA <50 copies/mL, n/N (%)
ITT: Observed ITT: M = F ITT: Observed ITT: M = F
Abacavir PI Abacavir PI Abacavir PI Abacavir PI
Baseline 52/52 
(100)
52/52 
(100)
52/52 
(100)
52/52 
(100)
42/52 
(81)
47/52 
(90)
42/52 
(81)
47/52 
(90)
4 49/49 
(100)
44/45 
(98)
49/52 
(94)
44/52 
(85)
48/49 
(98)
43/45 
(96)
48/52 
(92)
43/52 
(83)
8 39/42 
(93)
42/42 
(100)
39/52 
(75)
42/52 
(81)
38/42 
(90)
40/42 
(95)
38/52 
(73)
40/52 
(77)
12 38/41 
(93)
40/40 
(100)
38/52 
(73)
40/52 
(77)
38/41 
(93)
39/40 
(98)
38/52 
(73)
39/52 
(75)
20 38/41 
(93)
40/40 
(100)
38/52 
(73)
40/52 
(77)
32/41 
(78)
38/40 
(95)
32/52 
(62)
38/52 
(73)
28 36/40 
(90)
40/40 
(100)
36/52 
(69)
40/52 
(77)
32/40 
(80)
39/40 
(98)
32/52 
(62)
39/52 
(75)
Abbreviations: ITT = intent to treat; M = F = missing equals failure analysis; PI = protease inhibitor.BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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Results of the PMAQ-7 indicated significantly better
Scheduling and Timing scores in the abacavir-switch arm.
Significant improvement in this PMAQ-7 dimension was
similarly reported at 24 weeks in the PI-to-abacavir switch
study, COL30305 [33]. Improved scores in this dimen-
sion may have been related to the simpler, twice-daily
dosing of abacavir compared to the patients' previous PI-
containing regimens. The proportion of patients reporting
100% adherence previously was shown to be higher at 24
weeks in one PI-to-abacavir switch study (COL30305;
92% vs 68%) [33] and at 48 weeks in another
(CNA30017; 91% vs 76%) [29]. In these trials, better
adherence with the abacavir-containing regimen was
believed to be due at least in part to the relatively lower
pill count and absence of special dosing requirements
incurred by abacavir-containing HAART. The absence of a
significant difference in overall QOL between the
abacavir-switch and PI-continuation arms was not unex-
pected in view of the same finding being demonstrated on
the SF-36 at 24 weeks in COL30305 [33].
Switching to abacavir is just one of several switch strate-
gies that have been investigated to date in an attempt to
remedy hyperlipidemia in patients receiving PI-contain-
ing HAART. It is acknowledged that the ideal candidate for
this switch strategy is a patient started on triple therapy,
where pre-existing abacavir resistance is unlikely [30,32].
Another switch strategy-replacement of hyperlipidemia-
associated PIs with PIs that have a low likelihood of caus-
ing significant lipid elevation or adversely affecting the
total cholesterol:HDL cholesterol ratio (fosamprenavir or
atazanavir)-would be expected to improve lipid profiles in
HIV-infected patients [6-8,35]. Attempts to reduce lipids
by switching from a hyperlipidemia-associated PI to
NNRTIs have also been investigated [32,36-43]. More
favorable lipid effects appear to occur when a switch is
made to nevirapine than to efavirenz [42,43].
This study had several limitations. As patients in this study
had mean CD4+ cell counts >500 cells/mm3, they were
highly immunocompetent and may not be representative
of typical HIV-infected patients presenting to their physi-
cian with PI-associated hyperlipidemia. The study did not
evaluate the influence of NRTI background drugs on lipid
changes because the patients remained on the same base-
line NRTIs. This could have affected the results because
stavudine is known to elevate cholesterol and triglyceride
levels [44], whereas zidovudine and lamivudine do not.
Most studies have found that switching therapy tends to
be optimally effective in patients whose viral load is fully
suppressed for at least 6 months rather than the 3 months
in our study [45]. This shorter pre-study time of viral
suppression could have biased the virologic results against
abacavir, as could allowing prior suboptimal nucleoside
therapy. As we did not have information about prior NRTI
combinations that many patients received pre-study, we
could not assess whether these earlier NRTI combination
regimens had been inadequate. Lipid data for study
participants prior to their receipt of PI-containing regi-
mens were not available to the investigators; thus,
whether PIs were the cause of the patients' hyperlipidemia
could not be verified. Dietary intake and physical activity
assessments were not performed in this study to evaluate
whether either differed between the treatment arms.
Further valuable clinical information could have been
acquired from this study had switch agents in addition to
abacavir been used as comparators. In the only study of
this type that has been conducted to date – the Nevirap-
ine-Efavirenz-Abacavir (NEFA) Study – a significantly
lower proportion of stabilized HAART recipients (HIV-1
RNA <50 copies/mL for = 6 months) switching from a PI
to abacavir developed fasting plasma triglycerides >400
mg/dL and plasma cholesterol >240 mg/dL at 12 months
compared to treatment groups in which patients switched
from a PI to efavirenz or nevirapine [32]. Kaplan-Meier
estimates of the likelihood of reaching the primary treat-
ment end point (increase in HIV-1 RNA levels to ≥ 200
copies/mL, progression to AIDS, or death) in NEFA
showed no significant differences between treatments.
Median CD4+ cell counts increased above baseline simi-
larly in all three treatment arms (by 39–50 cells/mm3 at
12 months). However, the abacavir-switch arm had a sig-
nificantly lower incidence of adverse events than the efa-
virenz-switch and nevirapine-switch arms (41% vs 57%
and 54%, P= 0.03), a lower incidence of neuropsychiatric
adverse events than the efavirenz group (9% vs 31%;
Grade 3 or 4: 0.7% vs 14%), and significantly fewer cases
of discontinuation of study drug due to adverse events
(6% vs 17% and 17%, P= 0.01). Overall, NEFA, like our
study, indicated that abacavir was an appropriate drug to
substitute for PIs in HAART regimens as long as patients
were virologically suppressed pre-switch and minimally
antiretroviral-experienced. Our study differed from NEFA
in that all  participants in ESS40003 had PI-associated
hyperlipidemia at baseline (NEFA included only 7–13%
with triglycerides >400 mg/dL and 21–25% with total
cholesterol >240 mg/dL) and because our study used a
less stringent definition of virologic failure (HIV-1 RNA
>1000 copies/mL on two occasions at least 1 week apart
vs. HIV-1 RNA ≥ 200 copies/mL at ≥ 16 weeks, with sub-
sequent confirmation [NEFA]).
Conclusions
In conclusion, in antiretroviral-experienced patients with
HIV-1 RNA <50 copies/mL and CD4+ counts >500 cells/
mm3, substituting abacavir for hyperlipidemia-associated
PIs in HAART regimens improves lipid profiles and main-
tains virologic suppression over a 28-week period, and it
simplifies treatment.BMC Infectious Diseases 2005, 5:2 http://www.biomedcentral.com/1471-2334/5/2
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